Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 19/20 | 0.66 |
| ▸ | KIT | P10721 | 1/20 | 0.65 |
| ▸ | FLT3 | P36888 | 1/20 | 0.65 |
| ▸ | EGFR | P00533 | 3/20 | 0.64 |
| ▸ | LCK | P06239 | 2/20 | 0.61 |
| ▸ | ITK | Q08881 | 1/20 | 0.61 |
| ▸ | LYN | P07948 | 1/20 | 0.61 |
| ▸ | TEC | P42680 | 1/20 | 0.60 |
| ▸ | TXK | P42681 | 1/20 | 0.60 |
| ▸ | BMX | P51813 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19519304 | 0.88 | BTK (0.78) | BTKKITFLT3EGFRLCK | |
| SCHEMBL1613927 | 0.87 | BTK (0.67) | BTKEGFRTECTXKBMX | |
| SCHEMBL31279081 | 0.87 | BTK (0.79) | BTKFLT3EGFRLCKITK | |
| SCHEMBL11948322 | 0.87 | BTK (0.86) | BTKKITFLT3EGFRLCK | |
| SCHEMBL17951503 | 0.87 | BTK (0.86) | BTKKITFLT3EGFRLCK | |
| SCHEMBL25118714 | 0.86 | BTK (0.75) | BTKKITFLT3EGFRLCK | |
| SCHEMBL15314505 | 0.84 | BTK (0.67) | BTKKITFLT3EGFRLCK | |
| SCHEMBL6645874 | 0.84 | BTK (0.85) | BTKKITFLT3EGFRLCK | |
| SCHEMBL5801460 | 0.84 | BTK (0.77) | BTKEGFRLCKITKLYN | |
| SCHEMBL5801655 | 0.83 | BTK (0.71) | BTKKITFLT3EGFRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012463-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140080844-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| EP-2650294-A1 | Inhibitors of Bruton's Tyrosine Kinase | Pharmacyclics, Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| US-20110086866-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086866-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | BTK 2/4885KIT 692/4885FLT3 139/4885 |
| US-20140080844-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | BTK 2/4885KIT 692/4885FLT3 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.